Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Value Market Research | PRODUCT CODE: 1936942

Cover Image

PUBLISHER: Value Market Research | PRODUCT CODE: 1936942

Global Hospital Acquired Disease Testing Market Size, Share, Trends & Growth Analysis Report 2026-2034

PUBLISHED:
PAGES: 122 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF & Excel (Single User License)
USD 3920
PDF & Excel (10-user License)
USD 4730
PDF & Excel (Corporate User License)
USD 7430

Add to Cart

The Hospital Acquired Disease Testing Market size is expected to reach USD 77.92 Billion in 2034 from USD 18.20 Billion (2025) growing at a CAGR of 17.54% during 2026-2034.

The hospital-acquired disease testing market is set to experience robust growth, driven by the increasing incidence of healthcare-associated infections (HAIs) and the growing emphasis on patient safety and quality of care. As hospitals and healthcare facilities strive to minimize the risk of HAIs, the demand for accurate and rapid diagnostic testing methods is becoming paramount. The rise in antibiotic-resistant pathogens further complicates the landscape, necessitating advanced testing solutions that can quickly identify the causative agents of infections and guide appropriate treatment strategies. This growing awareness of the impact of HAIs on patient outcomes and healthcare costs is propelling the market forward.

Technological advancements in diagnostic testing are revolutionizing the hospital-acquired disease testing market. Innovations such as molecular diagnostics, point-of-care testing, and next-generation sequencing are enhancing the speed and accuracy of pathogen detection. These technologies enable healthcare providers to implement timely interventions, reducing the duration of hospital stays and improving overall patient outcomes. Additionally, the integration of digital health solutions, including electronic health records and laboratory information systems, is streamlining data management and facilitating better communication among healthcare teams, further enhancing the efficiency of infection control measures.

Moreover, the hospital-acquired disease testing market will benefit from increased regulatory scrutiny and public health initiatives aimed at reducing HAIs. As healthcare organizations adopt stringent infection prevention protocols, the demand for comprehensive testing solutions will rise. Collaborative efforts between diagnostic companies, healthcare providers, and regulatory bodies will be essential in developing standardized testing guidelines and ensuring the widespread adoption of best practices. As the market evolves, the focus will shift towards integrating testing into broader infection control strategies, emphasizing the importance of surveillance, early detection, and targeted interventions in combating hospital-acquired diseases.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Test Type

  • Urinary Tract Infection
  • Surgical Site Infection
  • Pneumonia Stents
  • Blood Stream Infection
  • Methicillin-Resistant Staphylococcus Aureus
  • Others

By End User

  • Hospitals and Intensive Care Units (ICUS)
  • Ambulatory Surgical and Diagnostic Centers
  • Nursing Homes and Maternity Centers

COMPANIES PROFILED

  • Abbott, Eurofins Scientific, BIOMRIEUX, Cantel Medical, Meridian Bioscience, Inc, QIAGEN, F HoffmannLa Roche Ltd, BD, Hologic, Inc, Siemens Healthcare Private Limited, Thermo Fisher Scientific Inc, Medtronic, Getinge AB

We can customise the report as per your requriements

Product Code: VMR11213861

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL HOSPITAL ACQUIRED DISEASE TESTING MARKET: BY TEST TYPE 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Test Type
  • 4.2. Urinary Tract Infection Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Surgical Site Infection Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Pneumonia Stents Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.5. Blood Stream Infection Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.6. Methicillin-Resistant Staphylococcus Aureus Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL HOSPITAL ACQUIRED DISEASE TESTING MARKET: BY END USER 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast End User
  • 5.2. Hospitals and Intensive Care Units (ICUS) Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Ambulatory Surgical and Diagnostic Centers Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.4. Nursing Homes and Maternity Centers Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL HOSPITAL ACQUIRED DISEASE TESTING MARKET: BY REGION 2022-2034(USD MN)

  • 6.1. Regional Outlook
  • 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.2.1 By Test Type
    • 6.2.2 By End User
    • 6.2.3 United States
    • 6.2.4 Canada
    • 6.2.5 Mexico
  • 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.3.1 By Test Type
    • 6.3.2 By End User
    • 6.3.3 United Kingdom
    • 6.3.4 France
    • 6.3.5 Germany
    • 6.3.6 Italy
    • 6.3.7 Russia
    • 6.3.8 Rest Of Europe
  • 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.4.1 By Test Type
    • 6.4.2 By End User
    • 6.4.3 India
    • 6.4.4 Japan
    • 6.4.5 South Korea
    • 6.4.6 Australia
    • 6.4.7 South East Asia
    • 6.4.8 Rest Of Asia Pacific
  • 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.5.1 By Test Type
    • 6.5.2 By End User
    • 6.5.3 Brazil
    • 6.5.4 Argentina
    • 6.5.5 Peru
    • 6.5.6 Chile
    • 6.5.7 South East Asia
    • 6.5.8 Rest of Latin America
  • 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.6.1 By Test Type
    • 6.6.2 By End User
    • 6.6.3 Saudi Arabia
    • 6.6.4 UAE
    • 6.6.5 Israel
    • 6.6.6 South Africa
    • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

  • 7.1. Recent Developments
  • 7.2. Company Categorization
  • 7.3. Supply Chain & Channel Partners (based on availability)
  • 7.4. Market Share & Positioning Analysis (based on availability)
  • 7.5. Vendor Landscape (based on availability)
  • 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL HOSPITAL ACQUIRED DISEASE TESTING INDUSTRY

  • 8.1. Top Companies Market Share Analysis
  • 8.2. Company Profiles
    • 8.2.1 Abbott
    • 8.2.2 Eurofins Scientific
    • 8.2.3 BIOMRIEUX
    • 8.2.4 Cantel Medical
    • 8.2.5 Meridian BioscienceInc
    • 8.2.6 QIAGEN
    • 8.2.7 F. Hoffmann-La Roche Ltd
    • 8.2.8 BD
    • 8.2.9 HologicInc
    • 8.2.10 Siemens Healthcare Private Limited
    • 8.2.11 Thermo Fisher Scientific Inc
    • 8.2.12 Medtronic
    • 8.2.13 Getinge AB
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!